Lymphoma

A051901

Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (NIVO-MR2) Induction followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma

A151804

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

A211901

Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions

Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) in diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release

EAY191

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

EZH-302

SYMPHONY-1: A Phase 1B/3 Double-blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat/EPZ-6438 or Placebo in Combination with Lenalidomide plus Rituximab (R^2) in Subjects with Relapsed/Refractory Follicular Lymphoma

GO43878

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients with Relapsed/Refractory Mantle Cell Lymphoma

GRAIL-MA-002

REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study)

INCA-34176-357

A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

JCAR017-EAP-001

Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release

KT-US-472-0141

Expanded access to commercially out-of-specification brexucabtagene autoleucel for the treatment of adult patients diagnosed with an FDA approved labeled indication

WVU010922

Prospective Evaluation of Xerava (Eravacycline) Prophylaxis in Hematological Malignancy Patients with Prolonged Neutropenia